The Link Between Human Cytomegalovirus (HCMV) and Hypertension
NCT01113359 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2010-04-29
Summary
It has been reported that mouse cytomegalovirus infection alone can elevate the blood pressure in mice. Since HCMV has uniquely evolved with its human host, with little genetic similarity to the animal CMV counterparts, and it only replicates in human, an epidemiological study is required to define the relevance of HCMV infection and expression of hcmv-miRNA-UL112 to the pathogenesis of essential hypertension.
The investigators found that hcmv-miR-UL112, a human cytomegalovirus (HCMV)-encoded miRNA, was highly expressed in the hypertensive patients. Among the top miRNA target predictions, the investigators demonstrate that IRF-1 is a direct target gene of hcmv-miR-UL112, along with MICB that has been previously reported. Both IRF-1 and MICB play critical roles in immuno/inflammatory and anti-infection response. Thus, the investigators speculated that IRF-1 and MICB repression by hcmv-miR-UL112 could be considered a unifying mechanism that evades the host response at several levels: antiviral, inflammatory, and immune. In addition, there is an increasing evidence that IRF-1 may be important in apoptosis, angiogenesis, neointima formation and the pathogenesis of vascular diseases. IRF-1 can up-regulate angiotensin II type 2 receptor (AGTR2) that exerts antiproliferative and proapoptotic actions and affects regulation of blood pressure. It has been reported that the targeted disruption of the mouse AGTR2 gene resulted in a significant increase in blood pressure and increased sensitivity to angiotensin II. The nitric oxide synthase expression and NO synthesis in macrophages and distinct cardiomyocytes are induced and controlled by IRF-1 in response to inflammation, important steps in vascular biology that may improve endothelial function and inhibit smooth muscle cell migration, and a key pathophysiological event in hypertension. Collectively, these reports support a strong relationship between IRF-1 regulation and hypertension, indicating a potential role of hcmv-miR-UL112 and HCMV infection in the pathogenesis of hypertension.Thus, the investigators want to investigate the potential link between HCMV infection and essential hypertension.
Conditions
- HCMV Infection
- Hypertension
Sponsors & Collaborators
-
Beijing Chao Yang Hospital
lead OTHER
Principal Investigators
-
Xin-Chun Yang, MD · Beijing Chao Yang Hospital
Eligibility
- Min Age
- 30 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-04-30
- Primary Completion
- 2010-05-31
- Completion
- 2010-05-31
Countries
- China
Study Locations
More Related Trials
-
CMV Infection in Adolescent Males
NCT00302029 ·Status: TERMINATED
-
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
NCT04280380 ·Status: UNKNOWN
-
Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress
NCT01397058 ·Status: UNKNOWN
-
Genotyping of Cytomegalovirus From Patients in Israel
NCT00228202 ·Status: UNKNOWN
-
Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
NCT02782988 ·Status: COMPLETED
-
Cytomegalovirus Spread and Reactivation in Blood Cells
NCT00006314 ·Status: COMPLETED
-
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
NCT02798692 ·Status: COMPLETED ·Phase: PHASE1
-
HCMV Breakthrough Infections During Letermovir Prophylaxis
NCT06339892 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection
NCT03369912 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals
NCT06694428 ·Status: RECRUITING
-
CMV-associated Immunomodulation in Renal Transplant Patients
NCT06976008 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study
NCT02843880 ·Status: TERMINATED
-
A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
NCT04225923 ·Status: COMPLETED ·Phase: PHASE2
-
The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University
NCT02642822 ·Status: COMPLETED
-
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
NCT04690933 ·Status: COMPLETED
-
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
NCT01753167 ·Status: COMPLETED ·Phase: PHASE2
-
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
NCT00466817 ·Status: COMPLETED ·Phase: PHASE3
-
Cytomegalovirus Reactivation in ICU Patients Requiring Prolong Mechanical Ventilation
NCT06520605 ·Status: RECRUITING
-
A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
NCT05958186 ·Status: COMPLETED
-
Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
NCT04916704 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
NCT05089630 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients
NCT01833416 ·Status: COMPLETED
-
Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults
NCT02826798 ·Status: COMPLETED ·Phase: PHASE1
-
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
NCT03443791 ·Status: COMPLETED ·Phase: NA
-
Cytomegalovirus Reactivation in Non Immunocompromised Patients Undergoing Cardiac Surgery
NCT02527291 ·Status: COMPLETED